SMAD2 and Hepatic fibrosis: The results of the hepatic fibrosis study reinforce our findings in renal fibrosis, where TA’s inhibition of the TGF-β/Smad2/3 cascade parallels its effects on other fibrotic pathways observed in liver fibrosis.